Collaboration, License and Other Arrangements (Tables)

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Allocation of Consideration Assets Acquired and Liabilities Assumed

The total cash paid to acquire Alpine, allocation of consideration to the assets acquired and liabilities assumed and AIPR&D was as follows:

	(in millions)
Cash consideration to acquire Alpine’s outstanding common stock	$	4,536.9
Cash consideration for Alpine’s vested and unvested equity awards	420.6
Total cash consideration paid to Alpine	4,957.5
Less: Expense related to unvested equity awards	(197.6)
Transaction costs	40.7
Total consideration allocated	$	4,800.6
Cash and cash equivalents	$	31.9
Current marketable securities	209.5
Long-term marketable securities	48.5
Deferred tax asset	105.5
Total other assets	19.5
Total liabilities	(37.5)
Total identifiable assets acquired, net	377.4
Acquired in-process research and development expense	4,423.2
Total consideration allocated	$	4,800.6

Schedule of Credits Recognized in Condensed Consolidated Statements of Income (Loss)

During the three and nine months ended September 30, 2025 and 2024, the credits recognized in our condensed consolidated statements of income (loss) for CRISPR’s share of CRISPR JDCA activities were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
	(in millions)
Cost of sales	$	43.3	$	15.8	$	109.6	$	47.5
Research and development expenses	$	14.3	$	11.7	$	45.4	$	35.0
Acquired in-process research and development expenses	$	—	$	—	$	12.5	$	—